Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Approximately 3% of all human T-lymphotropic virus type 1 (HTLV-1)–infected persons will develop a disabling inflammatory disease of the central nervous system known as HTLV-1–associated myelopathy/tropical spastic paraparesis, against which there is currently no efficient treatment. As correlation exists between the proviral load (PVL) and the clinical status of the carrier, it is thought that diminishing the PVL could prevent later occurrence of the disease. We have conducted a study combining valproate, an inhibitor of histone deacetylases, and azidothymidine, an inhibitor of reverse transcriptase, in a series of baboons naturally infected with simian T-lymphotropic virus type 1 (STLV-1), whose PVL was equivalent to that of HTLV-1 asymptomatic carriers. We show that the combination of drugs caused a strong decrease in the PVL and prevented the transient rise in PVL that is seen after treatment with histone deacetylases alone. We then demonstrate that the PVL decline was associated with an increase in the STLV-1–specific cytotoxic T-cell population. We conclude that combined treatment with valproate to induce viral expression and azidothymidine to prevent viral propagation is a safe and effective means to decrease PVL in vivo. Such treatments may be useful to reduce the risk of HAM/TSP in asymptomatic carriers with a high PVL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043
Yoshida, M., Miyoshi, I., & Hinuma, Y. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2031 · Cited by 2,169
Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Self-citationJeffery, K. J. M., Usuku, K., Hall, S. E., Matsumoto, W., Taylor, G. P., Procter, J., Bunce, M., Ogg, G. S., Welsh, K. I., Weber, J. N., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3848 · Cited by 419
Self-citationCell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells
Jones, K. S., Petrow-Sadowski, C., Huang, Y. K., Bertolette, D. C., & Ruscetti, F. W. (2008) · Nature Medicine · doi:10.1038/nm1745 · Cited by 284
Jeffery, K. J. M., Siddiqui, A. A., Bunce, M., Lloyd, A. L., Vine, A. M., Witkover, A. D., Izumo, S., Usuku, K., Welsh, K. I., Osame, M., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7278 · Cited by 222
Self-citationSilencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms
Taniguchi, Y., Nosaka, K., Yasunaga, J.-I., Maeda, M., Mueller, N., Okayama, A., & Matsuoka, M. (2005) · Retrovirology · doi:10.1186/1742-4690-2-64 · Cited by 209
Taylor, G. P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, P., Usuku, K., et al. (2006) · Retrovirology · doi:10.1186/1742-4690-3-63 · Cited by 117
Self-citationAlteration of Blood–Brain Barrier Integrity by Retroviral Infection
Afonso, P. V., Ozden, S., Cumont, M.-C., Seilhean, D., Cartier, L., Rezaie, P., Mason, S., Lambert, S., Huerre, M., Gessain, A., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000205 · Cited by 112
Self-citationKira, J.-I., Fujihara, K., Itoyama, Y., Goto, I., & Hasuo, K. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90192-a · Cited by 96
Cited by
Futsch, N., Mahieux, R., & Dutartre, H. (2017) · Viruses · doi:10.3390/v10010001 · Cited by 155
“Thus, a combination of ZDV and IFN-α should be considered as the gold standard first-line therapy in leukemic subtypes of ATLL, and its use is already established in France, the United Kingdom and Florida, but not in Japan, where the Japanese national health insurance system did not approve its use.”
BackgroundInfluentialSelf-citationSafety of long-term treatment of HAM/TSP patients with valproic acid
Olindo, S., Belrose, G., Gillet, N., Rodriguez, S., Boxus, M., Verlaeten, O., Asquith, B., Bangham, C., Signaté, A., Smadja, D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-349910 · Cited by 52
Self-citationAntiviral effect of raltegravir on HTLV-1 carriers
Trevino, A., Parra, P., Bar-Magen, T., Garrido, C., de Mendoza, C., & Soriano, V. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr404 · Cited by 49
Barski, M. S., Minnell, J. J., & Maertens, G. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01877 · Cited by 37
STLV-1 as a model for studying HTLV-1 infection
Jégado, B., Kashanchi, F., Dutartre, H., & Mahieux, R. (2019) · Retrovirology · doi:10.1186/s12977-019-0503-0 · Cited by 27
Self-citation
Metadata
- Authors
- Afonso, P. V., Mekaouche, M., Mortreux, F., Toulza, F., Moriceau, A., Wattel, E., Gessain, A., Bangham, C. R. M., Dubreuil, G., Plumelle, Y., Hermine, O., Estaquier, J., & Mahieux, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-11-11
- Volume
- 116
- Issue
- 19
- Pages
- 3802-3808
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2055760934
- Cited by
- 81
- References
- 13
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. https://app.cochat.ai/papers/10.1182/blood-2010-02-270751
- The paper
- Afonso, P. V., Mekaouche, M., Mortreux, F., Toulza, F., Moriceau, A., Wattel, E., Gessain, A., Bangham, C. R. M., Dubreuil, G., Plumelle, Y., Hermine, O., Estaquier, J., & Mahieux, R. (2010). Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. https://doi.org/10.1182/blood-2010-02-270751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.